In accordance with these studies, we also observed significant differences in both PFS and OS of patients in AI fit and unfit groups, indicating that AI eligibility is related to prolonged PFS and OS in patients with NSCLC harboring an EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.